[S-20] シンポジウム20

[S-20-4] Clinical development of Efgartigimod and ARGX-117 for Treatment of Neurological Diseases

Peter Ulrichts (Chief Scientific Officer, argenx BV)

Peter obtained a PhD in immunology from the university of Ghent (Belgium). After a short post-doc period, he joined argenx in 2010 as research scientist where he was involved in the development of various therapeutic antibodies for the treatment of cancer and autoimmune diseases. In 2013, he headed the development of argenx’ FcRn antagonist Efgartigimod until the first-in-human study after which he transitioned to become the lead scientist of the efgartigimod program. Currently, he holds the position of Chief Scientific Officer and oversees the development of all clinical and pre-clinical compounds within the argenx pipeline.